Volume 3 (2013) // Issue 1 // e-ISSN 2224-3453

European Association of NeuroOncology Magazine

 $Neurology \cdot Neurosurgery \cdot Medical \ Oncology \cdot Radiotherapy \cdot Paediatric \ Neuro-oncology \cdot Neuropathology \cdot Neuroradiology \cdot Neuroimaging \cdot Nursing \cdot Patient \ Issues$

Case Report: Primary CNS Lymphoma: An Unusual Case of Prolonged Response to Steroids and Extended Survival (21 Years) Bosa C, Bertero L, Trevisan E Ruda R *European Association of NeuroOncology Magazine 2013; 3 (1)* 27-28



Homepage:

<u>www.kup.at/</u> journals/eano/index.html

Online Database Featuring Author, Key Word and Full-Text Search



THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY

Member of the

Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · 3003 Gablitz, Austria

Primary CNS Lymphoma: An Unusual Case of Prolonged Response to Steroids and Extended Survival (21 Years)

Chiara Bosa, Luca Bertero, Elisa Trevisan, Roberta Rudà

From the Department of Neuro-Oncology, University and Città della Salute e della Scienza, Turin, Italy

Case Report

In 1991, a 27-year-old man presented at the emergency department of a country hospital with diplopia, tickling paraesthesia, and a right-sided hemiparesis. He underwent contrastenhanced brain MRI which documented a lesion with inhomogeneous enhancement in the right paramedian pontine region. Other examinations (CSF analysis with isoelectric focussing, EMG, SSEP) were negative and steroids (dexamethasone 8 mg/d) were then administered with clinical improvement.

The MRI examinations at 1 and 6 months after steroid therapy were stable and the patient remained asymptomatic.

In 2007, 16 years after the first episode, the man was admitted to our hospital with dizziness and diplopia. Contrast-enhanced MRI showed multiple enhancing areas in the right cerebellar hemisphere, the floor of the fourth ventricle, and the mesencephalic-diencephalic region. The original pontine lesion on brain MRI was unchanged and spine MRI was normal (Figures 1A, 1B). The patient was extensively investigated (systemic work-up and CSF analysis), and the spectrum of steroid-responsive non-neoplastic lesions in the CNS (multiple sclerosis, neurosarcoidosis, Behçet disease, and atypical tuberculosis) was ruled out. Primary central nervous system lymphoma (PCNSL) was then suspected. An HIV serum test was negative. The patient refused a biopsy, then was treated



EUR ASSOC NEUROONCOL MAG 2013; 3 (1) 27

For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH.



Figure 3. Hematoxylin and eosin staining, CD20 staining, and Ki67 staining.



Figure 4: T1-weighted MR images with gadolinium after treatment with high-dose methotrexate and whole-brain radiotherapy.

with steroids and complete clinical and radiological remission was achieved.

In April 2009, at the age of 45, the patient presented again at the emergency department with headache, vomiting, and dizziness. We performed contrast-enhanced brain MRI which showed a new, large enhancing lesion in the left cerebellum with distortion of the fourth ventricle but no evidence of hydrocephalus (Figures 2A, 2B).

The lesion was surgically partially resected and the histological diagnosis was that of diffuse large B-cell lymphoma (Figure 3). The examinations performed for the staging of lymphoma (contrast-enhanced spine MRI, CSF analysis, chest-abdomen CT scan, whole-body PET scan, testicular ultrasound, and bone marrow biopsy) ruled out systemic involvement.

The patient started chemotherapy with high-dose methotrexate (3.5 gr/m^2 body surface every 2 weeks). He completed 6 cycles with good tolerance and nCR (near complete response) on MRI. Wholebrain radiotherapy (WBRT; 36 Gy + boost of 9 Gy) was then performed. At the first brain MRI performed after the end of treatment (December 2009) complete response was observed (Figures 4A, 4B) and subsequent serial MRI examinations showed no recurrence (last MRI performed in January 2012). The patient is now neurologically normal without cognitive deficits and is continuing follow-up with MRI every 6 months.

Comment

Primary CNS lymphoma, when affecting young and immunocompetent subjects and being located in critical areas for biopsy, can present diagnostic problems at onset. Treatment with steroids can lead to a regression of lesions in up to 40 % of patients, thus deferring the definite histological diagnosis.

Our case shows some peculiar features: a long disease history (overall, 21 years) with multiple recurrences involving exclusively the brain stem, cerebellum, and thalamus; an unusual and protracted response to steroids

Ferreri AJ. How I treat primary CNS lym-

Gerstner ER, Batchelor TT. Primary central

nervous system lymphoma. Arch Neurol

Schäfer N, Glas M, Herrlinger U. Primary

Rev Neurother 2012; 12: 1197-206

CNS lymphoma: a clinician's guide. Expert

phoma. Blood 2011; 118: 510-22.

2010:67:291-7

alone and complete response to standard chemo- and radiotherapies even if performed very late (18 years after the onset of symptoms).

Further Reading:

Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009; 6: 587–97.

Clarke JL, Deangelis LM. Primary central nervous system lymphoma. Handb Clin Neurol 2012; 105: 517–27.

Correspondence to: Roberta Rudà, MD Department of Neuro-Oncology University and San Giovanni Battista Hospital Via Cherasco 15, 10126 Torino, Italy E-mail: rudarob@hotmail.com